ruxolitinib,bms-986158,fedratinib
incyte,novartis,bms
['#mpn', 'rux,(-crux),(-trux),(-deruxtecan)', 'ruxolitinib', 'bms-986158', 'rux,(-crux),(-trux)', 'fedra', 'bms']
treatment with bet inhibitor bms-986158 plus ruxolitinib or fedratinib resulted in a notable reduction in splenic volume with a manageable safety profile. #mpn #eha2023 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.